Is LKFT or EPRX more profitable?

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Lakefront Biotherapeutics American Depositary Shares N/A N/A N/A Eupraxia Pharmaceuticals N/A -63.97% -43.32%

Does the media prefer LKFT or EPRX?

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 3 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.22 beat Lakefront Biotherapeutics American Depositary Shares' score of 1.06 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lakefront Biotherapeutics American Depositary Shares 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VIR or EPRX more profitable?

Vir Biotechnology's return on equity of -29.99% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Vir Biotechnology N/A -29.99% -23.62% Eupraxia Pharmaceuticals N/A -63.97% -43.32%

Does the media favor VIR or EPRX?

In the previous week, Vir Biotechnology had 20 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 23 mentions for Vir Biotechnology and 3 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.22 beat Vir Biotechnology's score of 0.24 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vir Biotechnology 4 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AGIO or EPRX?

In the previous week, Agios Pharmaceuticals had 5 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 3 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.22 beat Agios Pharmaceuticals' score of -0.01 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ZYME or EPRX?

In the previous week, Zymeworks had 4 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 7 mentions for Zymeworks and 3 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.22 beat Zymeworks' score of 0.68 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is EPRX or PVLA more profitable?

Palvella Therapeutics' return on equity of -47.84% beat Eupraxia Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Eupraxia Pharmaceuticals N/A -63.97% -43.32% Palvella Therapeutics N/A -47.84% -38.33%

Does the media refer more to EPRX or PVLA?

In the previous week, Palvella Therapeutics had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 5 mentions for Palvella Therapeutics and 3 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.22 beat Palvella Therapeutics' score of 0.09 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eupraxia Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Eupraxia Pharmaceuticals (EPRX) Competitors

$6.68 -0.64 (-8.74%)

Closing price 04:00 PM Eastern

Extended Trading

$6.71 +0.03 (+0.43%)

As of 05:34 PM Eastern

Compare

EPRX vs. LKFT, VIR, AGIO, ZYME, and PVLA

Should you buy Eupraxia Pharmaceuticals stock or one of its competitors? Eupraxia Pharmaceuticals's main competitors and comparable companies include Lakefront Biotherapeutics American Depositary Shares (LKFT), Vir Biotechnology (VIR), Agios Pharmaceuticals (AGIO), Zymeworks (ZYME), and Palvella Therapeutics (PVLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Eupraxia Pharmaceuticals compare to Lakefront Biotherapeutics American Depositary Shares?

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.

Lakefront Biotherapeutics American Depositary Shares has higher revenue and earnings than Eupraxia Pharmaceuticals. Lakefront Biotherapeutics American Depositary Shares is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lakefront Biotherapeutics American Depositary Shares	$1.26B	1.55	$363.05M	-$1.41	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A

Lakefront Biotherapeutics American Depositary Shares presently has a consensus price target of $37.00, suggesting a potential upside of 25.13%. Eupraxia Pharmaceuticals has a consensus price target of $17.80, suggesting a potential upside of 143.17%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Lakefront Biotherapeutics American Depositary Shares.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lakefront Biotherapeutics American Depositary Shares	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.56
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

32.5% of Lakefront Biotherapeutics American Depositary Shares shares are owned by institutional investors. 2.9% of Lakefront Biotherapeutics American Depositary Shares shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Lakefront Biotherapeutics American Depositary Shares' return on equity of 0.00% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%

In the previous week, Lakefront Biotherapeutics American Depositary Shares and Lakefront Biotherapeutics American Depositary Shares both had 3 articles in the media. Eupraxia Pharmaceuticals' average media sentiment score of 1.22 beat Lakefront Biotherapeutics American Depositary Shares' score of 1.06 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lakefront Biotherapeutics American Depositary Shares	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lakefront Biotherapeutics American Depositary Shares has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Summary

Eupraxia Pharmaceuticals beats Lakefront Biotherapeutics American Depositary Shares on 8 of the 14 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Vir Biotechnology?

Vir Biotechnology (NASDAQ:VIR) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Vir Biotechnology's return on equity of -29.99% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vir Biotechnology	N/A	-29.99%	-23.62%
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%

Vir Biotechnology has a beta of 1.59, suggesting that its stock price is 59% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 0.83, suggesting that its stock price is 17% less volatile than the broader market.

In the previous week, Vir Biotechnology had 20 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 23 mentions for Vir Biotechnology and 3 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.22 beat Vir Biotechnology's score of 0.24 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vir Biotechnology	4 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

65.3% of Vir Biotechnology shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Vir Biotechnology. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vir Biotechnology	$68.56M	27.89	-$437.99M	-$1.86	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A

Vir Biotechnology currently has a consensus price target of $21.86, indicating a potential upside of 93.43%. Eupraxia Pharmaceuticals has a consensus price target of $17.80, indicating a potential upside of 143.17%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eupraxia Pharmaceuticals is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vir Biotechnology	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Summary

Vir Biotechnology beats Eupraxia Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Agios Pharmaceuticals?

Agios Pharmaceuticals (NASDAQ:AGIO) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment.

Agios Pharmaceuticals presently has a consensus price target of $41.50, suggesting a potential upside of 34.65%. Eupraxia Pharmaceuticals has a consensus price target of $17.80, suggesting a potential upside of 143.17%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Agios Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.55
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -418.24%. Agios Pharmaceuticals' return on equity of -35.67% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%

In the previous week, Agios Pharmaceuticals had 5 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 8 mentions for Agios Pharmaceuticals and 3 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.22 beat Agios Pharmaceuticals' score of -0.01 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Agios Pharmaceuticals. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	34.05	-$412.78M	-$7.01	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A

Agios Pharmaceuticals has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Summary

Eupraxia Pharmaceuticals beats Agios Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Zymeworks?

Zymeworks (NASDAQ:ZYME) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Zymeworks presently has a consensus target price of $40.64, indicating a potential upside of 60.43%. Eupraxia Pharmaceuticals has a consensus target price of $17.80, indicating a potential upside of 143.17%. Given Eupraxia Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Zymeworks.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zymeworks	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

92.9% of Zymeworks shares are held by institutional investors. 33.5% of Zymeworks shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Zymeworks has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

In the previous week, Zymeworks had 4 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 7 mentions for Zymeworks and 3 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.22 beat Zymeworks' score of 0.68 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zymeworks	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eupraxia Pharmaceuticals has a net margin of 0.00% compared to Zymeworks' net margin of -405.31%. Eupraxia Pharmaceuticals' return on equity of -63.97% beat Zymeworks' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zymeworks	-405.31%	-72.30%	-37.18%
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Zymeworks. Zymeworks is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zymeworks	$105.96M	16.96	-$81.13M	-$2.02	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A

Summary

Eupraxia Pharmaceuticals beats Zymeworks on 9 of the 16 factors compared between the two stocks.

How does Eupraxia Pharmaceuticals compare to Palvella Therapeutics?

Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Palvella Therapeutics (NASDAQ:PVLA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Palvella Therapeutics had 2 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 5 mentions for Palvella Therapeutics and 3 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.22 beat Palvella Therapeutics' score of 0.09 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eupraxia Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Palvella Therapeutics' return on equity of -47.84% beat Eupraxia Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%
Palvella Therapeutics	N/A	-47.84%	-38.33%

Eupraxia Pharmaceuticals currently has a consensus price target of $17.80, indicating a potential upside of 143.17%. Palvella Therapeutics has a consensus price target of $207.43, indicating a potential upside of 54.36%. Given Eupraxia Pharmaceuticals' higher possible upside, analysts plainly believe Eupraxia Pharmaceuticals is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

Eupraxia Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.27, indicating that its share price is 127% less volatile than the broader market.

40.1% of Palvella Therapeutics shares are owned by institutional investors. 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Palvella Therapeutics. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Eupraxia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A
Palvella Therapeutics	$42.81M	45.23	-$41.72M	-$4.83	N/A

Summary

Palvella Therapeutics beats Eupraxia Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get Eupraxia Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EPRX vs. The Competition

Export

Metric	Eupraxia Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$434.33M	$3.82B	$7.16B	$13.16B
Dividend Yield	N/A	3.65%	2.52%	20.73%
P/E Ratio	-6.55	12.90	275.97	25.79
Price / Sales	N/A	1,176.95	617.33	101.37
Price / Cash	N/A	39.46	27.30	36.12
Price / Book	4.74	16.95	10.68	6.03
Net Income	-$38.58M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-13.70%	-4.83%	-3.17%	-3.04%
1 Month Performance	-20.67%	-12.20%	-6.61%	-5.16%
1 Year Performance	10.41%	8.87%	3.69%	-2.48%

Eupraxia Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EPRX Eupraxia Pharmaceuticals	3.0263 of 5 stars	$6.68 -8.7%	$17.80 +166.5%	+20.6%	$434.33M	N/A	N/A	49	High Trading Volume
LKFT Lakefront Biotherapeutics American Depositary Shares	3.0303 of 5 stars	$29.51 -1.6%	$37.00 +25.4%	-13.3%	$1.98B	$990.57M	N/A	1,310	Positive News
VIR Vir Biotechnology	2.7174 of 5 stars	$11.12 -3.5%	$21.86 +96.6%	+94.8%	$1.95B	$68.56M	N/A	367
AGIO Agios Pharmaceuticals	3.0414 of 5 stars	$31.92 +0.4%	$41.50 +30.0%	-24.1%	$1.90B	$54.03M	N/A	540
ZYME Zymeworks	2.8428 of 5 stars	$25.26 -4.8%	$40.64 +60.9%	+40.3%	$1.88B	$37.13M	N/A	264

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EPRX) was last updated on 10/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. LKFT, VIR, AGIO, ZYME, and PVLA

How does Eupraxia Pharmaceuticals compare to Lakefront Biotherapeutics American Depositary Shares?

Summary

How does Eupraxia Pharmaceuticals compare to Vir Biotechnology?

Summary

How does Eupraxia Pharmaceuticals compare to Agios Pharmaceuticals?

Summary

How does Eupraxia Pharmaceuticals compare to Zymeworks?

Summary

How does Eupraxia Pharmaceuticals compare to Palvella Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eupraxia Pharmaceuticals (EPRX) Competitors

EPRX vs. LKFT, VIR, AGIO, ZYME, and PVLA

How does Eupraxia Pharmaceuticals compare to Lakefront Biotherapeutics American Depositary Shares?

Which has higher earnings & valuation, LKFT or EPRX?

Do analysts rate LKFT or EPRX?

Do insiders and institutionals have more ownership in LKFT or EPRX?

Is LKFT or EPRX more profitable?

Does the media prefer LKFT or EPRX?

Which has more volatility and risk, LKFT or EPRX?

Summary

How does Eupraxia Pharmaceuticals compare to Vir Biotechnology?

Is VIR or EPRX more profitable?

Which has more risk & volatility, VIR or EPRX?

Does the media favor VIR or EPRX?

Do institutionals & insiders hold more shares of VIR or EPRX?

Which has higher earnings and valuation, VIR or EPRX?

Do analysts rate VIR or EPRX?

Summary

How does Eupraxia Pharmaceuticals compare to Agios Pharmaceuticals?

Do analysts recommend AGIO or EPRX?

Is AGIO or EPRX more profitable?

Does the media prefer AGIO or EPRX?

Which has stronger valuation & earnings, AGIO or EPRX?

Which has more volatility and risk, AGIO or EPRX?

Summary

How does Eupraxia Pharmaceuticals compare to Zymeworks?

Do analysts rate ZYME or EPRX?

Do insiders and institutionals believe in ZYME or EPRX?

Which has more volatility and risk, ZYME or EPRX?

Does the media prefer ZYME or EPRX?

Is ZYME or EPRX more profitable?

Which has preferable earnings & valuation, ZYME or EPRX?

Summary

How does Eupraxia Pharmaceuticals compare to Palvella Therapeutics?

Does the media refer more to EPRX or PVLA?

Is EPRX or PVLA more profitable?

Do analysts rate EPRX or PVLA?

Which has more risk and volatility, EPRX or PVLA?

Do institutionals and insiders believe in EPRX or PVLA?

Which has preferable earnings and valuation, EPRX or PVLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX vs. The Competition

Eupraxia Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools